Medication for opioid use disorder service delivery in carceral facilities: update and summary report
Abstract The opioid overdose crisis intersects critically with the criminal legal system where individuals with opioid use disorder (are significantly overrepresented. Subsequently, incarceration increases the risk of opioid overdose due to reduced tolerance, interrupted social supports, and limited...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Health & Justice |
| Online Access: | https://doi.org/10.1186/s40352-025-00317-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571956238483456 |
|---|---|
| author | Justin Berk Anna-Maria South Megan Martin Michael-Evans James Cameron Miller Lawrence Haber Josiah Rich |
| author_facet | Justin Berk Anna-Maria South Megan Martin Michael-Evans James Cameron Miller Lawrence Haber Josiah Rich |
| author_sort | Justin Berk |
| collection | DOAJ |
| description | Abstract The opioid overdose crisis intersects critically with the criminal legal system where individuals with opioid use disorder (are significantly overrepresented. Subsequently, incarceration increases the risk of opioid overdose due to reduced tolerance, interrupted social supports, and limited access to treatment. Medications for opioid use disorder (MOUD), such as methadone, buprenorphine, and naltrexone, have been shown to reduce opioid-related mortality and improve outcomes for those in carceral settings. Despite this, access to MOUD in jails and prisons remains limited due to stigma, concerns about medication diversion, and logistical challenges. This paper reviews the current state of knowledge on MOUD in carceral settings, summarizing the prevalence of treatment programs, the role of novel formulations like injectable buprenorphine, and barriers to implementation. It also explores the continuum of care, emphasizing the importance of initiating MOUD during incarceration and ensuring continuation upon release to prevent treatment gaps. Recent policy changes, such as Sect. 1115 Medicaid waivers, offer promising avenues for expanding access, but retention in treatment and post-release outcomes remain significant challenges. The paper provides a comprehensive overview of existing literature and updates on MOUD service delivery, including the impact of recent policy shifts and research on outcomes such as recidivism and health improvement. It concludes by identifying key areas for future research, including strategies to improve treatment retention, address systemic barriers through criminal justice reform, and enhance care coordination during the transition from incarceration to the community. |
| format | Article |
| id | doaj-art-ca70c3e70b754203bff4ffa7a742a783 |
| institution | Kabale University |
| issn | 2194-7899 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Health & Justice |
| spelling | doaj-art-ca70c3e70b754203bff4ffa7a742a7832025-02-02T12:12:55ZengBMCHealth & Justice2194-78992025-02-0113111210.1186/s40352-025-00317-9Medication for opioid use disorder service delivery in carceral facilities: update and summary reportJustin Berk0Anna-Maria South1Megan Martin2Michael-Evans James3Cameron Miller4Lawrence Haber5Josiah Rich6Alpert Medical School at Brown UniversityUniversity of Kentucky, Division of Hospital Medicine and Addiction Consult and Education Service, Department of Medicine, University of Kentucky College of MedicineAlpert Medical School at Brown UniversityAlpert Medical School at Brown UniversityAlpert Medical School at Brown UniversityDenver Health and Hospital Authority, Division of Hospital Medicine, Department of Medicine, University of ColoradoAlpert Medical School at Brown UniversityAbstract The opioid overdose crisis intersects critically with the criminal legal system where individuals with opioid use disorder (are significantly overrepresented. Subsequently, incarceration increases the risk of opioid overdose due to reduced tolerance, interrupted social supports, and limited access to treatment. Medications for opioid use disorder (MOUD), such as methadone, buprenorphine, and naltrexone, have been shown to reduce opioid-related mortality and improve outcomes for those in carceral settings. Despite this, access to MOUD in jails and prisons remains limited due to stigma, concerns about medication diversion, and logistical challenges. This paper reviews the current state of knowledge on MOUD in carceral settings, summarizing the prevalence of treatment programs, the role of novel formulations like injectable buprenorphine, and barriers to implementation. It also explores the continuum of care, emphasizing the importance of initiating MOUD during incarceration and ensuring continuation upon release to prevent treatment gaps. Recent policy changes, such as Sect. 1115 Medicaid waivers, offer promising avenues for expanding access, but retention in treatment and post-release outcomes remain significant challenges. The paper provides a comprehensive overview of existing literature and updates on MOUD service delivery, including the impact of recent policy shifts and research on outcomes such as recidivism and health improvement. It concludes by identifying key areas for future research, including strategies to improve treatment retention, address systemic barriers through criminal justice reform, and enhance care coordination during the transition from incarceration to the community.https://doi.org/10.1186/s40352-025-00317-9 |
| spellingShingle | Justin Berk Anna-Maria South Megan Martin Michael-Evans James Cameron Miller Lawrence Haber Josiah Rich Medication for opioid use disorder service delivery in carceral facilities: update and summary report Health & Justice |
| title | Medication for opioid use disorder service delivery in carceral facilities: update and summary report |
| title_full | Medication for opioid use disorder service delivery in carceral facilities: update and summary report |
| title_fullStr | Medication for opioid use disorder service delivery in carceral facilities: update and summary report |
| title_full_unstemmed | Medication for opioid use disorder service delivery in carceral facilities: update and summary report |
| title_short | Medication for opioid use disorder service delivery in carceral facilities: update and summary report |
| title_sort | medication for opioid use disorder service delivery in carceral facilities update and summary report |
| url | https://doi.org/10.1186/s40352-025-00317-9 |
| work_keys_str_mv | AT justinberk medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport AT annamariasouth medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport AT meganmartin medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport AT michaelevansjames medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport AT cameronmiller medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport AT lawrencehaber medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport AT josiahrich medicationforopioidusedisorderservicedeliveryincarceralfacilitiesupdateandsummaryreport |